EP2596366A4 - Polythérapie basée sur des inhibiteurs de mdm2 et efgr - Google Patents

Polythérapie basée sur des inhibiteurs de mdm2 et efgr

Info

Publication number
EP2596366A4
EP2596366A4 EP11810417.3A EP11810417A EP2596366A4 EP 2596366 A4 EP2596366 A4 EP 2596366A4 EP 11810417 A EP11810417 A EP 11810417A EP 2596366 A4 EP2596366 A4 EP 2596366A4
Authority
EP
European Patent Office
Prior art keywords
mdm2
combination therapy
efgr
inhibitors
efgr inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11810417.3A
Other languages
German (de)
English (en)
Other versions
EP2596366A1 (fr
Inventor
Benjamin Mugrage
Ignatius Turchi
Matthew Sills
Jane Ong
John Allocco
Pam Wines
Margarita Bastos
Joseph P Errico
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ERRICO, JOSEPH P.
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/020414 external-priority patent/WO2011085126A2/fr
Application filed by Individual filed Critical Individual
Publication of EP2596366A1 publication Critical patent/EP2596366A1/fr
Publication of EP2596366A4 publication Critical patent/EP2596366A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11810417.3A 2010-07-21 2011-07-21 Polythérapie basée sur des inhibiteurs de mdm2 et efgr Withdrawn EP2596366A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36648010P 2010-07-21 2010-07-21
PCT/US2011/020414 WO2011085126A2 (fr) 2010-01-06 2011-01-06 Méthodes et compositions pour le développement de médicaments ciblés
US12/986,146 US8618302B2 (en) 2010-01-06 2011-01-06 Methods and compositions of targeted drug development
PCT/US2011/020418 WO2011085129A2 (fr) 2010-01-06 2011-01-06 Méthodes et compositions pour le développement de médicaments ciblés
PCT/US2011/044882 WO2012012653A1 (fr) 2010-07-21 2011-07-21 Polythérapie basée sur des inhibiteurs de mdm2 et efgr

Publications (2)

Publication Number Publication Date
EP2596366A1 EP2596366A1 (fr) 2013-05-29
EP2596366A4 true EP2596366A4 (fr) 2014-04-16

Family

ID=45497182

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11810417.3A Withdrawn EP2596366A4 (fr) 2010-07-21 2011-07-21 Polythérapie basée sur des inhibiteurs de mdm2 et efgr

Country Status (3)

Country Link
EP (1) EP2596366A4 (fr)
CA (1) CA2805658C (fr)
WO (1) WO2012012653A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858565A1 (fr) * 2011-12-07 2013-07-04 Duke University Procedes d'identification et d'utilisation d'inhibiteurs de mdm2
US20150150869A1 (en) 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2922544B1 (fr) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 avec des dérivés de quinoléine
WO2015017788A1 (fr) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Méthode permettant de prédire la sensibilité d'un cancer
EP3063302B1 (fr) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Procédés de détermination de la chimiosensibilité et de la chimiotoxicité
EP3388419A1 (fr) * 2017-04-12 2018-10-17 Leadiant Biosciences SA Inhibiteurs de gli1 et utilisations associées

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037343A1 (fr) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibiteurs de l'interaction entre mdm2 et p53
WO2009117484A2 (fr) * 2008-03-18 2009-09-24 University Of South Florida Petite molécule inhibitrice d'e2f
US20100160313A1 (en) * 2008-10-22 2010-06-24 University Of Southern California Discovery of novel anticancer compounds based on conformational sampling of quinoxalinhydrazide pharmacophore
WO2011082175A2 (fr) * 2009-12-31 2011-07-07 Zacharon Pharmaceuticals, Inc. Inhibiteurs de glycosaminoglycane
WO2011085126A2 (fr) * 2010-01-06 2011-07-14 Errico Joseph P Méthodes et compositions pour le développement de médicaments ciblés

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470665T1 (de) * 2006-03-22 2010-06-15 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037343A1 (fr) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibiteurs de l'interaction entre mdm2 et p53
WO2009117484A2 (fr) * 2008-03-18 2009-09-24 University Of South Florida Petite molécule inhibitrice d'e2f
US20100160313A1 (en) * 2008-10-22 2010-06-24 University Of Southern California Discovery of novel anticancer compounds based on conformational sampling of quinoxalinhydrazide pharmacophore
WO2011082175A2 (fr) * 2009-12-31 2011-07-07 Zacharon Pharmaceuticals, Inc. Inhibiteurs de glycosaminoglycane
WO2011085126A2 (fr) * 2010-01-06 2011-07-14 Errico Joseph P Méthodes et compositions pour le développement de médicaments ciblés

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERKSON R G ET AL: "Pilot screening programme for small molecule activators of p53", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 115, no. 5, 10 July 2005 (2005-07-10), pages 701 - 710, XP008129829, ISSN: 0020-7136, [retrieved on 20050223], DOI: 10.1002/IJC.20968 *
DUTTA ET AL: "Cellular responses to EGFR inhibitors and their relevance to cancer therapy", CANCER LETTERS, NEW YORK, NY, US, vol. 254, no. 2, 8 September 2007 (2007-09-08), pages 165 - 177, XP022182281, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2007.02.006 *
IAN R HARDCASTLE: "Inhibitors of the MDM2-p53 interaction as anticancer drugs", DRUGS OF THE FUTURE 2007, PROUS SCIENCE, vol. 32, no. 10, 1 January 2007 (2007-01-01), pages 883 - 896, XP007919174, DOI: 10.1358/DOF.2007.032.10.1131965 *
See also references of WO2012012653A1 *

Also Published As

Publication number Publication date
CA2805658A1 (fr) 2012-01-26
CA2805658C (fr) 2016-12-13
EP2596366A1 (fr) 2013-05-29
WO2012012653A1 (fr) 2012-01-26

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
GB201012175D0 (en) Procedure and mechanisms
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
IL222481A0 (en) Combination therapy
EP2542086A4 (fr) Composés et utilisations thérapeutiques associées
EP2552323A4 (fr) Polythérapie
ZA201208173B (en) Peptices and their use
EP2558137A4 (fr) Procédés et combinaison
HRP20182083T1 (hr) Nova kombinacija i uporaba
EP2648736A4 (fr) Composés cycloalkylguanidines inhibiteurs de la f1f0-atpase et leurs utilisations
IL212760A0 (en) Internal and external disc shunts alleviate back pain
EP2596366A4 (fr) Polythérapie basée sur des inhibiteurs de mdm2 et efgr
EP2624854A4 (fr) Modulateurs de la moésine et leurs utilisations
GB201011411D0 (en) Therapeutic compounds and their use
EP2629766A4 (fr) Polythérapie
EP2638160A4 (fr) Nuclions et ribocapsides
GB201102215D0 (en) Inventions and therapy
GB201102239D0 (en) Inventions and therapy
GB201102238D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy
GB201102210D0 (en) Inventions and therapy
GB201102212D0 (en) Inventions and therapy
GB201102208D0 (en) Inventions and therapy
GB201102228D0 (en) Inventions and therapy
GB201102227D0 (en) Inventions and therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ERRICO, JOSEPH P.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140319

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/517 20060101ALI20140313BHEP

Ipc: A61K 45/06 20060101ALI20140313BHEP

Ipc: A61K 31/4709 20060101AFI20140313BHEP

Ipc: A61P 35/00 20060101ALI20140313BHEP

17Q First examination report despatched

Effective date: 20150623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160105